𝛼SK or Search

ENTITY

JW Therapeutics (2126 HK)

41

Analysis

Health Care • China

JW Therapeutics is a clinical-stage cell therapy company focused on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T therapy. The company is headquartered in Shanghai, China, and was founded in 2016.

more

Refresh

Exchange Announcement • 24 Sep 2026 16:33

2026 Interim Report

Exchange Announcement • 27 Aug 2026 17:57

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 12 Aug 2026 16:31

Notice Of Board Meeting

Exchange Announcement • 26 Jun 2026 20:28

List Of Directors And Their Roles And Function

Exchange Announcement • 26 Jun 2026 20:08

(1) Poll Results Of The Annual General Meeting Held On June 26, 2026; (2) Retirement Of Directors, Change Of Chairman; And (3) Change In Composition Of Board Committee

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x